CAS: 847559-80-2; 2-Amino-4-(2,4-Dichloro-5-(2-(Pyrrolidin-1-yl)Ethoxy)Phenyl)-N-Ethylthieno[2,3-D]Pyrimidine-6-Carboxamide

结构式图片

上下游产品

2-amino-4-(2,4-dichloro-5-hydroxyphenyl)thieno[2,3-d]pyrimidine-6-carboxylic acid ethylamide 1-(2-chloroethyl)pyrrolidine hydr°Chloride

合成工艺路线路线简述

  • 7250-67-1 + 847559-68-6 = 847559-80-2
    反应条件:1.1 Reagents: Cesium Carbonate Solvents: Dimethylformamide; 1 H,100 °C; Cooled
    标题:Combining Hit Identification Strategies: Fragment-Based And In Silico Approaches To Orally Active 2-Aminothieno[2,3-D]Pyrimidine Inhibitors Of The Hsp90 Molecular Chaperone
    作者:Brough,Paul A.; Barril,Xavier; Borgognoni,Jenifer; Chene,Patrick; Davies,Nicholas G. M.; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2009 卷标:52(15) 页码:4794-4809
📜2-Amino-4-(2,4-Dichloro-5-Hydroxyphenyl)-N-Ethylthieno[2,3-D]Pyrimidine-6-Carboxamide,N-(2-氯乙基)吡咯烷盐酸盐置于caesium Carbonate体系中,用 N,N-二甲基甲酰胺 作为反应溶剂,以48%的收率获得产物nvp-Bep 800; 2-氨基-4-[2,4-二氯-5-[2-(1-吡咯烷基)乙氧基]苯基]-N-乙基噻吩并[2,3-D]嘧啶-6-甲酰胺
参考文献:结合命中识别策略:基于片段和in Silico方法的hsp90分子伴侣的口服活性2-氨基噻吩并[2,3-D]嘧啶抑制剂
标题:结合命中识别策略:基于片段和in Silico方法的hsp90分子伴侣的口服活性2-氨基噻吩并[2,3-D]嘧啶抑制剂
摘要:Hsp90分子伴侣的抑制剂作为治疗癌症的潜在分子治疗剂已显示出可观的前景.在这里,我们描述了新型的2-Aminothieno [2,3-D]嘧啶atp竞争性hsp90抑制剂,该抑制剂是通过结合基于片段和计算机模拟筛选产生的独特的低亲和性命中的结构元素以及来自x-的结构信息而设计的射线蛋白质晶体学.该系列的示例具有很高的亲和力(ic 50在荧光极化(fp)竞争性结合试验中测得hsp90为50-100 Nm),并且在人类癌细胞系中具有活性,它们抑制细胞增殖并表现出致癌蛋白消耗和hsp72随之升高的特征.当在人bt474人乳腺癌异种移植模型中口服施用时,几个实例(34A,34D和34I)以非常好耐受的剂量引起肿瘤生长消退.
DOI:10.1021/jm900357Y

海关参考信息

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Mshaik R, Simonet J, Georgievski A, Jamal L, Bechoua S, Ballerini P, Bellaye PS, Mlamla Z, Pais de Barros JP, Geissler A, Francin PJ, Girodon F, Garrido C, Quéré R. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias. Blood Cancer J. 2021 Mar 18;11(3):61. doi: 10.1038/s41408-021-00450-2.
2: Stingl L, Stühmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer. 2010 May 25;102(11):1578-91. doi: 10.1038/sj.bjc.6605683.
3: Hartmann S, Günther N, Biehl M, Katzer A, Kuger S, Worschech E, Sukhorukov VL, Krohne G, Zimmermann H, Flentje M, Djuzenova CS. Hsp90 inhibition by NVP- AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines. Cancer Lett. 2013 May 1;331(2):200-10. doi: 10.1016/j.canlet.2012.12.027. Epub 2013 Jan 20. 42(5):112445. doi: 10.1016/j.celrep.2023.112445. Epub 2023 May 2. 16(1):72. doi: 10.1186/s12943-017-0640-9.

合成参考文献


摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知